Literature DB >> 15694337

Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation.

Eric J Bennett1, Neil F Bence, Rajadas Jayakumar, Ron R Kopito.   

Abstract

The highly conserved ubiquitin-proteasome system (UPS) controls the stability of most nuclear and cytoplasmic proteins and is therefore essential for virtually all aspects of cellular function. We have previously shown that the UPS is impaired in the presence of aggregated proteins that become deposited into cytoplasmic inclusion bodies (IBs). Here, we report that production of protein aggregates specifically targeted to either the nucleus or cytosol leads to global impairment of UPS function in both cellular compartments and is independent of sequestration of aggregates into IBs. The observation of severe UPS impairment in compartments lacking detectable aggregates or aggregation-prone protein, together with the lack of interference of protein aggregates on 26S proteasome function in vitro, suggests that UPS impairment is unlikely to be a consequence of direct choking of proteasomes by protein aggregates. These data suggest a common proteotoxic mechanism for nuclear and cytoplasmic protein aggregates in the pathogenesis of neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694337     DOI: 10.1016/j.molcel.2004.12.021

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  191 in total

1.  HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells.

Authors:  J I-Ju Leu; Julia Pimkina; Pooja Pandey; Maureen E Murphy; Donna L George
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

2.  20S proteasome activation promotes life span extension and resistance to proteotoxicity in Caenorhabditis elegans.

Authors:  Niki Chondrogianni; Konstantina Georgila; Nikos Kourtis; Nektarios Tavernarakis; Efstathios S Gonos
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

3.  Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease.

Authors:  Juliette D Godin; Ghislaine Poizat; Miriam A Hickey; Florence Maschat; Sandrine Humbert
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

Review 4.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 5.  Roles for the ubiquitin-proteasome pathway in protein quality control and signaling in the retina: implications in the pathogenesis of age-related macular degeneration.

Authors:  Fu Shang; Allen Taylor
Journal:  Mol Aspects Med       Date:  2012-04-10

Review 6.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

7.  Amyloid β-induced FOXRED2 mediates neuronal cell death via inhibition of proteasome activity.

Authors:  SangMi Shim; WonJae Lee; HaeWon Chung; Yong-Keun Jung
Journal:  Cell Mol Life Sci       Date:  2010-10-23       Impact factor: 9.261

Review 8.  Integration of clearance mechanisms: the proteasome and autophagy.

Authors:  Esther Wong; Ana Maria Cuervo
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-11-10       Impact factor: 10.005

9.  Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.

Authors:  Siddhartha Mitra; Andrey S Tsvetkov; Steven Finkbeiner
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

10.  Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes.

Authors:  Manish K Gupta; James Gulick; Ruijie Liu; Xuejun Wang; Jeffery D Molkentin; Jeffrey Robbins
Journal:  Circ Res       Date:  2014-08-05       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.